Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma (NCT01771107)
This pilot phase I/II trial studies the side effects and the best dose of brentuximab vedotin (also known as SGN-035) and combination chemotherapy work in treating patients with stage II-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma.
Monoclonal antibody-drug conjugates or ADCs such as brentuximab vedotin can block cancer growth by finding cancer cells and causing them to die. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.
This trial is sponsored by the National Cancer Institute (NCI). 
- Condition: Hodgkin Lymphoma
- Drugs used in this trial
- Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- dacarbazine (DTIC-Dome®; Bayer Pharmaceuticals Corporation)/li>
- doxorubicin hydrochloride (Doxil®; TTY Bio pharmacy Company Limited)
- vinblastine (Velban®; Eli Lilly and Company)
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Phase: I & II
- Estimated Enrollment: 51
- Start: March 2013
- Estimated Completion: June 2018 (Final data collection date for primary outcome measure)
- Last verified: May 2015
- Last updated: August 6, 2015
Last Editorial review: July 21, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.